Regulatory and funding agencies are increasingly calling for the use of patient-reported outcome measures in all fields of healthcare. [1] [2] [3] Within ophthalmology, many instruments are in use for measuring disability and quality of life related to cataracts, 4 diabetic retinopathy, 5 agerelated macular degeneration, 6 glaucoma, 7 and refractive error. 8 Uncorrected refractive error (URE) is a major cause of visual impairment and blindness worldwide. It is estimated that between 98-153 million people have distance vision worse than 20/60 due to URE. 9, 10 Such impairments are associated with decreased quality of life and visual function. [11] [12] [13] Accordingly, the WHO has made refractive error correction a priority in their global campaign to eliminate global blindness: Vision 2020 -The Right to Sight. 14, 15 The burden of URE is disproportionately borne by persons living in developing countries, 15, 16 with nearly a quarter of those with distance visual impairment living in India. 9 The global economic burden of URE has been estimated at $269 billion dollars in productivity losses, and provision of care for affected individuals. 17, 18 Although the treatment of refractive error with spectacles is technically straightforward, poor access to refractive services and high costs limit universal correction in the developing world. [19] [20] [21] Academic, private and humanitarian groups are engaged in spectacle provision for both ametropia and presbyopia in developing countries, some of whom have utilized ready-made spectacles (RMS). [22] [23] [24] [25] The cost of refractive error correction is partially driven by the fact that custom spectacles (CS) need to be made to order with unique spherical and cylindrical power for each eye, and frequently cannot be dispensed at the time of prescribing. RMS can be factory made in bulk using the same spherical power in both eyes, in limited diopter steps, frame sizes and styles. RMS can be dispensed immediately as long as the appropriate inventory is maintained. Theoretically the majority of a population should have acceptable vision with RMS. [26] [27] [28] We have recently reported visual acuity and patient-reported planned continued use of RMS compared with CS in children in China 25, 29 and adults in India, 24 and found a comparable degree of acceptability.
In order to determine if RMS are acceptable to a population, validated patient-reported outcome measures play a critical role. We recently reported the validation of a novel visual function and quality of life instrument using Rasch analysis in an urban Indian population. 30 In the present study, we use this instrument to compare RMS versus CS in a randomized, prospective, doublemasked trial in Delhi, India.
Subjects and Methods
The study design has been described in detail elsewhere. 24 Briefly, the performance of RMS was compared with CS using a prospective, short term (1-month) double-masked randomized clinical trial. The Johns Hopkins Medicine Institutional Review Board and the Dr Shroff's Charity Eye Hospital (SCEH) Human Research Ethics Committee approved the study protocol and this clinical trial was registered with the US National Institutes of Health Protocol Registration System (http://clinicaltrials.gov NCT00657670; last accessed 3/2/2012). The research adhered to the tenets of the Declaration of Helsinki.
Between May and September 2008, 400 adults presenting for care at the SCEH clinic and outreach screening camps in Delhi, India were recruited for participation in this study. All participants were refracted prior to study enrollment using a standardized protocol 24 and randomized to receive either the CS prescription based on the full sphero-cylindrical correction or RMS prescription based on the spherical equivalent (SE) for the eye with lower refractive error but limited to the 25 powers in the RMS inventory. Eligible participants were 18-45 years of age, had habitual vision of 20/40 or worse in the better-seeing eye, at least 1 diopter (D) of spherical refractive error and were willing to return for follow-up study visits. Study follow-up was conducted at one-month. Study enrollment and follow-up are summarized in Figure 1 . Of the initial 400 participants, 10 were excluded due to presenting vision > 20/40 and 27 were lost to follow-up; this analysis is limited to the 363 eligible participants (RMS, n = 183; CS, n = 180) with baseline and follow-up measures. We used an intent-to-treat approach. There were nine errors in spectacle orders whereby 7 participants allocated to RMS received their full correction and 2 allocated to CS received bilateral spheres. Data analyses were repeated for treatment received. We did not impute outcome measures to address missing follow-up data.
Randomization
The research optometrists, coordinator and study subjects were masked to the allocation of spectacles and remained masked during all visits. After completion of the randomization visit, both the CS and RMS prescriptions, pupillary distance, frame choice and participant identification number were sent to the dispensing optical shop. The optical technician then referred to a computer-generated randomization grid (www.randomization.com accessed April 1, 2008) with 400 entries and ordered the spectacles according to the group allocation for the specific participant identification number. There was no opportunity for the optical shop technician to change a subject's identification number or move the participant to a different location on the randomization table. The spectacles were verified as ordered by a technician at the optical shop prior to being dispensed. Masking was maintained during all follow-up assessments because the spectacles were manufactured at an optical facility separate from the testing site, and the RMS and CS were identical in gross appearance. Additionally, those involved in data collection were not equipped to measure refractive power of the spectacles during assessment and thereby remained masked to the treatment allocation during all evaluations. was piloted, modified, and validated using Rasch analysis. Logit scores from Rasch analysis of the 16-item questionnaire provided an interval measure of participant ability, including mobility, social interaction, and visual symptoms at baseline and follow-up. 30 Patient satisfaction was assessed on a five-point Likert scale using the question "During the past four weeks, how satisfied have you been with your vision?" where 0 = Very dissatisfied, 1 = Dissatisfied, 2 = Neither satisfied nor dissatisfied, 3 = Satisfied, and 4 = Very satisfied. A secondary outcome in this analysis was distance visual acuity. Visual acuity was measured using tumbling E-charts (Precision Vision, Villa Park, IL, USA) with retro-illumination. Visual acuity was scored with 0.02 logMAR (logarithm of Minimum Angle of Resolution) assigned to each letter. All measures were assessed at baseline and follow-up.
Outcome measures

Statistical design and methods
The primary objective of the analysis was to determine whether receipt of ready-made or custom-made spectacles affected patient-reported visual function and quality of life and visionrelated satisfaction. Responses were scored using Rasch analysis (Andrich model) in WinSteps software (ver. 3.67, Chicago, IL) to produce interval scores for each participant based on their responses to the 16-item Visual Function and Quality of Life Instrument at baseline and onemonth follow-up. All other analyses were conducted in Stata 11 (College Station, Texas). Chisquare tests assessed the difference in distributions of Rasch scores between groups at baseline and follow-up. To evaluate differences in mean outcome measures between the RMS and CS group for baseline, follow-up, and change measures, we used t-tests with a significant Type I error rate of 5%. We had pre-specified secondary analyses of the impact of astigmatism and anisometropia on the effect size in the study protocol and thus, sensitivity analyses were conducted to determine mean differences in patient-reported outcomes between study groups among participants with astigmatism ≥2.00D and anisometropia ≥1.00D. Multivariable analyses were conducted to examine the effect of group on change in Rasch score and patient satisfaction, controlling for residual confounding by demographic and vision-related characteristics. Interaction terms were introduced to the final multivariable regression models for both outcomes to test for the presence of effect modification by astigmatism or anisometropia.
The study was powered to be able to detect a 15% difference in the primary outcome of the overall study (rate of continued use of spectacles) at a 5% level of significance with 80% power assuming base rate of continued use of 70%. We enrolled 200 subjects into each arm assuming a loss to follow-up rate of 10-15% to provide a target 175 in each arm. Our pilot data for the patient reported outcomes instrument 30 suggested we would be able to measure a difference of 0.5 logits (power 80%, statistical significance 5%) with this sample size.
Results
The average age in our study population was 30.4 years and nearly 60% were female. Participants were generally healthy with few comorbidities. Approximately 55% of the population reported education at the secondary level or below and 79% had annual household income less than 60,000 Indian Rupees (RP; approximately United States Dollars (USD)=1500). Though more than half had worn spectacles previously, their presenting vision was on average 20/70 +1 (logMAR = 0.56). A small proportion had complex refractive error such as anisometropia (8%) and 12% had more than 2 diopters of astigmatism ( Table 1 ). The only significant difference between the two intervention groups was that the custom spectacle group was more likely to have reported seeing an ophthalmologist before.
The distribution of Rasch scores for the Visual Function and Quality of Life instrument are presented in Figure 2 , panel A and B by study group and time of assessment. Lower scores represent worse function and reduced quality of life. At baseline, the Rasch scores were approximately normally distributed and did not differ between groups (Chi-square p = 0.567). The second panel in the figure demonstrates left-skewed Rasch scores representing an increase in visual function and quality of life over the one-month follow-up; there was no difference in distribution of Rasch follow-up scores between the RMS and CS groups (Chisquare p = 0.600).
Mean Rasch scores, and patient satisfaction Likert scale scores did not differ between study groups as measured at baseline, one-month follow-up or by assessing change in outcome from baseline to follow-up. In the full sample, visual function and quality of life increased by an average of 3.23 logits (95% Confidence Interval (CI): 2.90-3.56) in the RMS group and an average of 3.61 logits (95% CI: 3.34-3.88) in the CS group. Mean patient satisfaction also increased by 1.83 points (95% CI: 1.60-2.06) on the Likert scale in the RMS group and 2.04 points (95% CI: 1.83-2.24) in the CS group. While there was not a statistically significant difference at follow-up in mean change for Rasch score and satisfaction between study groups in stratified analyses of participants with astigmatism or anisometropia, the magnitude of these changes was larger in the CS group. A change of 0.1 logMAR in visual acuity, which represents one line on a Snellen chart, was associated with a 2.71 logit increase in Rasch score over the study period (p < 0.001) (Figure 3) .
Results from bivariate analyses of demographic and vision-related characteristics and change in Rasch score are presented as unadjusted regression coefficients in Table 2 . The only significant predictor of change in Rasch score in the bivariate analyses was astigmatism greater than two diopters in both eyes. In the multivariable linear regression model, the custom spectacles group reported marginally significant improvements in visual function and quality of life compared to the ready-made spectacles group, equivalent to a 0.45 logit increase in the Rasch score (95% CI: 0.02 -0.88), controlling for age, gender, marital status, education, household income, astigmatism greater than two diopters in both eyes, anisometropia greater than one diopter, pupil size greater than four millimeters, and presenting vision worse than 20/63 in the better-seeing eye. In addition, astigmatism greater than two diopters in both eyes at baseline was negatively associated with change in visual function and quality of life, controlling for all other variables in the model (-0.99 logits; 95% CI: -1.68 --0.30). Tests for interaction indicate that there was statistically significantly improved visual function and quality of life among those with custom spectacles compared to RMS in those with astigmatism (2.00 logits; 95% CI: 0.72 -3.28) and anisometropia (2.13 logits; 95% CI: 0.62 -3.64) (model not shown).
Bivariate and multivariable linear regression models for change in satisfaction were also developed. Intervention group was not a significant predictor of change in satisfaction in either model. In bivariate analyses of demographic and vision-related characteristics, education, household income, pupil size greater than four millimeters, and astigmatism greater than two diopters in both eyes were negatively associated with change in satisfaction. In the full multivariable model, income 60,000-120,000 RP compared to income <60,000 RP (-0.50 points; 95% CI: -0.96 --0.04), astigmatism greater than two diopters in both eyes (-0.72 points; 95% CI: -1.21 -0.23), and pupil size greater than 4 millimeters (-0.33 points; 95% CI: -0.66 --0.01) were negatively associated with change in satisfaction, controlling for all other variables in the model. The addition of an interaction term between study group and astigmatism to the full model indicates that there is a statistically significant increase in patient satisfaction among those with custom spectacles versus RMS in this subgroup (1.23 points; 95% CI; 0.33 -2.14) (model not shown).
Discussion
This double-masked randomized clinical trial in urban India demonstrates that ready-made spectacles (RMS) produce similar changes in patient-reported outcomes of visual function, quality of life, and satisfaction with vision at one-month follow-up when compared to custom spectacles (CS). This is despite the fact that those in the RMS group did not have fully corrected vision. 24 With our previous findings on the equivalent uptake of ready-made spectacles and custom spectacles in this population, 24 this study supports more widespread use of ready-made spectacles in settings where custom spectacles are unavailable or unaffordable and refractive services are inaccessible to those in need.
The ability to use RMS as the foundation of outreach or humanitarian efforts to combat uncorrected refractive error is attractive for financial and practical reasons. Although the present study did not source actual RMS, the cost savings for the spectacles should be significant. 22 Additionally the ability to dispense spectacles at the time of refraction allows for dramatically simplified logistics, as long as an appropriate inventory of RMS is maintained.
We previously estimated that approximately 10% of this population would have refractive needs that are not met by RMS. 24, 25 Additionally, a recent review of global epidemiologic studies found rates ranging from 15.8 to 48.9% for astigmatism greater than 0.5 to 1.0 diopters. 33 In our study population, approximately 12% had astigmatism greater than 2.00 diopters, and this group had smaller gains in reported vision function and quality of life at follow-up, controlling for demographic and vision-related characteristics. Subgroup analyses show that there clearly are some who would be best served with custom spectacles. While these people are more likely to have higher degrees of astigmatism or anisometropia, the findings reported here and our prior reports from this dataset did not support the use of refractive cutoffs to exclude people from receiving RMS. Since RMS can be tried on immediately and worn in the vision testing setting, one could use this approach to identify persons who would not tolerate RMS well. Based on our findings, when integrating RMS into refractive service delivery, a mechanism should be in place to detect high levels of astigmatism and offer these individuals custom spectacles.
Visual function and quality of life was not associated with higher level of education or income, factors which could be associated with higher visual demand. Higher income and education were, however, associated with a reduced degree of improvement in satisfaction, though this was independent of treatment group assignment. It is still possible that individuals with unique spectacle needs could be expected to be the most discerning in a population, and so might be more likely to return for follow-up visits for dispensation should the decision to prescribe CS be made.
The use of a patient-reported outcome as a primary endpoint has pitfalls since it is, by its very nature, subjective. By using Rasch analysis to validate our visual function questionnaire, 30 we have demonstrated that our instrument is valid, mathematically robust, and well-targeted to this population. We showed a clinically important improvement in Rasch score of 3.23 and 3.61 logits in the RMS and CS groups respectively. This magnitude of this improvement is in line with change in logits after cataract extraction. 4 Additionally, results from our subgroup analyses show that there is a larger absolute difference between the change in Rasch scores in the CS compared to the RMS group within those patients with astigmatism >2.00D or anisometropia >1.00D. This provides a degree of face validity. Moreover, there was a clear positive linear relationship between improvement in visual acuity and improvement in Rasch score, demonstrating that our measure also has criterion validity. We had 21 subjects with astigmatism in both the RMS and CS groups and 15 subjects with anisometropia in both groups. While the findings of our study suggest improved patient satisfaction and vision-related quality of life in the CS group compared to the RMS group among the small number of participants with astigmatism or anisometropia, the study was underpowered to detect a clinically meaningful difference in these subgroups. Future studies with targeted recruitment of participants with astigmatism and anisometropia are needed to confirm that CS is preferable to RMS in these subgroups before designing programs without a "try-before-you-buy" option. Future research might also seek to address whether individuals with higher visual demand, either recreationally or professionally, have a preference for CS in the setting of astigmatism or anisometropia. Future research should seek to attain longer follow-up as long-term spectacle acceptance may not mirror our 1 month results. 34 Important strengths of the study include randomized design, large sample size, low loss to follow-up, and use of validated visual function instrument.
In conclusion, this research demonstrates similar large improvements in patient reported visual function with the provision of either ready-made or custom spectacles. We believe that the acceptability and affordability support the provision of RMS in those settings where CS are impractical, or where the cost of which would limit the number of those who could benefit. As resources permit, and access to refractive services improve, we expect more people opting to pay a premium for custom spectacles, but until that time, we predict high levels of satisfaction with ready-made spectacles. 
